SCHEMBL1303863

SCHEMBL1303863

OCC1OC(O)C(O)CC1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OGA O60502 4/20 0.39
SLC5A2 P31639 1/20 0.36
TK1 P04183 2/20 0.34
LMNA P02545 2/20 0.34
PIM1 P11309 1/20 0.34
CSNK2A2 P19784 1/20 0.34
CSNK2B P67870 1/20 0.34
CSNK2A1 P68400 1/20 0.34
CSNK2A3 Q8NEV1 1/20 0.34
ADRB1 P08588 1/20 0.34
DNMT1 P26358 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TK2 O00142 1/20 0.34
ALDH1A1 P00352 2/20 0.33
TSHR P16473 2/20 0.33
PDE4D Q08499 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
ADA P00813 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
ADORA2A P29274 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13092956 1.00 OGA (0.39) OGASLC5A2TK1LMNAPIM1
SCHEMBL13265415 1.00 OGA (0.39) OGASLC5A2TK1LMNAPIM1
SCHEMBL8819151 1.00 OGA (0.39) OGASLC5A2TK1LMNAPIM1
SCHEMBL13102723 1.00 OGA (0.39) OGASLC5A2TK1LMNAPIM1
SCHEMBL24760374 1.00 OGA (0.39) OGASLC5A2TK1LMNAPIM1
SCHEMBL16556942 1.00 OGA (0.39) OGASLC5A2TK1LMNAPIM1
SCHEMBL24943578 1.00 OGA (0.39) OGASLC5A2TK1LMNAPIM1
SCHEMBL12526525 1.00 OGA (0.39) OGASLC5A2TK1LMNAPIM1
SCHEMBL22065208 1.00 OGA (0.39) OGASLC5A2TK1LMNAPIM1
SCHEMBL13852188 1.00 OGA (0.39) OGASLC5A2TK1LMNAPIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115427049-A Inhibitors of malaria and plasmodium falciparum hexose transporters and uses thereof 清华大学 2022-12-02 CN claimed
US-20140080768-A1 PRODRUGS OF DHODH INHIBITORS AND THEIR USES BROWN RUDNICK LLP 2014-03-20 US claimed
CN-115427049-B Inhibitors of malaria and plasmodium falciparum hexose transporters and uses thereof 清华大学 2024-09-06 CN disclosed
CN-116615479-A Polyester polyols comprising 2, 5-bis (hydroxymethyl) tetrahydrofuran 巴斯夫欧洲公司 2023-08-18 CN disclosed
US-20230130134-A1 METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-04-27 US disclosed
CN-115427049-A Inhibitors of malaria and plasmodium falciparum hexose transporters and uses thereof 清华大学 2022-12-02 CN disclosed
US-20210128467-A1 MICRO-EMULSION CONTAINING CREATINE FATTY-ESTER, METHOD FOR PREPARING SAID MICRO-EMULSION AND USES THEREOF Commissariat à l'énergie atomique et aux énergies alternatives (FR) 2021-05-06 US disclosed
US-9850270-B2 Non-caloric sweeteners and methods for synthesizing CONAGEN INC. (US) 2017-12-26 US disclosed
US-20170362268-A1 STEVIOL GLYCOSIDE COMPOUNDS, COMPOSITIONS FOR ORAL INGESTION OR USE, AND METHOD FOR ENHANCING STEVIOL GLYCOSIDE SOLUBILITY CARGILL, INCORPORATED (US) 2017-12-21 US disclosed
EP-2982668-A2 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS Pharmacyclics LLC (US) 2016-02-10 EP disclosed
US-9181280-B2 Factor VIIa inhibitor PHARMACYCLICS LLC (US) 2015-11-10 US disclosed
US-20080275250-A1 Factor Viia Inhibitor PHARMACYCLICS, INC. (US) 2008-11-06 US disclosed
US-7375129-B2 Bis-indole pyrroles useful as antimicrobials agents NEREUS PHARMACEUTICALS, INC. (US) 2008-05-20 US disclosed
US-20070149601-A1 Bis-indole pyrroles useful as antimicrobials agents PRIVATE LIFE BIOMED AG (DE) 2007-06-28 US disclosed
US-20070078082-A1 Methods and compositions to treat glycosaminoglycan-associated molecular interactions NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2007-04-05 US disclosed
EP-1761504-A2 FACTOR VIIA INHIBITOR PHARMACYCLICS, INC. (US) 2007-03-14 EP disclosed
US-20060205942-A1 e.g. 2-{2-[545-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-5'-sulthmoyl-biphenyl-3-yl]-acetylsmino}-succinamic; anticoagulant, anticarcinogenic, antiinflammatory agent; deep vein thrombosis, rheumatoid arthritis, stroke PHARMACYCLICS LLC 2006-09-14 US disclosed
WO-2005118554-A2 FACTOR VIIA INHIBITOR PHARMACYCLICS, INC. (US) 2005-12-15 WO disclosed
EP-1569912-A2 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2005-09-07 EP disclosed
WO-2004050637-A2 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2004-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140080768-A1 PRODRUGS OF DHODH INHIBITORS AND THEIR USES DHODH, DPYD, DHFR OGA 362/4885SLC5A2 1063/4885TK1 535/4885
US-20210128467-A1 MICRO-EMULSION CONTAINING CREATINE FATTY-ESTER, METHOD FOR PREPARING SAID MICRO-EMULSION AND USES THEREOF FABP7, MTTP, CETP OGA 2865/4885SLC5A2 510/4885TK1 505/4885
US-20170362268-A1 STEVIOL GLYCOSIDE COMPOUNDS, COMPOSITIONS FOR ORAL INGESTION OR USE, AND METHOD FOR ENHANCING STEVIOL GLYCOSIDE SOLUBILITY SI, SORD, TAS2R13 OGA 880/4885SLC5A2 46/4885TK1 4414/4885
US-20060205942-A1 e.g. 2-{2-[545-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-5'-sulthmoyl-biphenyl-3-yl]-acetylsmino}-succinamic; anticoagulant, anticarcinogenic, antiinflammatory agent; deep vein thrombosis, rheumatoid arthritis, stroke F7, F9, F5 OGA 368/4885SLC5A2 3602/4885TK1 4807/4885
US-20070149601-A1 Bis-indole pyrroles useful as antimicrobials agents IDO1, IDO2, TPH1 OGA 4046/4885SLC5A2 4239/4885TK1 1084/4885
US-20230130134-A1 METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF G6PD, FBP1, ALDOA OGA 70/4885SLC5A2 25/4885TK1 173/4885
US-20070078082-A1 Methods and compositions to treat glycosaminoglycan-associated molecular interactions HPSE, CD44, CSGALNACT1 OGA 148/4885SLC5A2 1150/4885TK1 1831/4885
US-20080275250-A1 Factor Viia Inhibitor F7, F9, F5 OGA 1110/4885SLC5A2 4400/4885TK1 4540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.